Velafermin

Drug Profile

Velafermin

Alternative Names: CG-53135; CG53135-05; FGF 20; Fibroblast growth factor-20; rhFGF-20

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator CuraGen Corporation
  • Class Anti-inflammatories; Expectorants; Fibroblast growth factors
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Stomatitis

Most Recent Events

  • 10 Aug 2007 CuraGen completes enrolment in the CLN-12 trial for oral mucositis in the US
  • 01 Jun 2006 CuraGen has initiated enrolment in the CLN-12 trial for oral mucositis in the US, evaluating a single dose of velafermin
  • 24 Feb 2006 Data from a media release have been added to the adverse events and Mouth disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top